关键信息
-
基因名
RAET1G
- 应用
-
别名
RAET1G; ULBP5; UL-16 binding protein 5; Retinoic acid early transcript 1G protein
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q6H3X3
-
表达区间
1-213 aa
-
氨基酸序列
MAAAASPAILLRLPLLLLLSSWCRTGLADPHSLCYDITVIPKFRPGPRWRAVQGQVDEKTFLHYDCGSKTVTPVSPLGKKLNVTTAWKAQNPVLREVVDILTEQLLDIQLENYIPKEPLTLQARMSCEQKAEGHGSGSWQLSFDGQIFLLFDSENRMWTTVHPGARKMKEKWENDKDMTMSFHYISMGDCTGWLEDFLMGMDSTLEPSAGGTV
-
分子量
50.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
RAET1G is a member of the RAET1 family, which encodes for non-classical major histocompatibility complex (MHC) molecules. These molecules are integral to immune regulation, particularly in the recognition and response to cancer cells and viral infections. Research into RAET1G has gained momentum due to its potential role in modulating immune responses and influencing the behavior of immune cells, such as natural killer (NK) cells and T cells. It is expressed in various tissues and has been implicated in processes such as tumor immune evasion, making it a compelling target for immunotherapy. Studies have demonstrated that RAET1G can engage receptors like NKG2D on NK and T cells, leading to cellular activation and cytotoxic responses against tumor cells. However, the specific mechanisms by which RAET1G mediates immune interactions remain to be fully elucidated. Understanding these pathways could provide insights into designing novel therapeutic strategies, including vaccines or engineered immune cells, to enhance anti-tumor immunity. Ongoing research is focused on characterizing the structural properties of RAET1G protein and its interactions with immune receptors, which could lead to advancements in cancer treatment and broader applications in immunology.
